Navigation Links
Sinovac Completes Acquisition Aimed at Expanding Production Capacity
Date:2/15/2010

BEIJING, Feb. 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA), a leading China-based vaccine manufacturer, today announced the completion by its subsidiary, Sinovac Beijing, of the acquisition of buildings and land use rights. The total consideration for the purchase is approximately RMB120 million ($17.6 million), which will be financed from working capital. The initial payment of RMB56.5 million ($8.3 million) will be paid before February 20, 2010 and the balance of the purchase price will be paid in three installments within three years.

Sinovac Beijing is acquiring five existing buildings with a total built- out area of 32,322.66 square meters on 29,021.61 square meters of land, located in Changping District, Beijing, about half hour driving away from our headquarter. The site was previously used to manufacture medicinal products. Sinovac plans to set up two new production lines with a combined annual production capacity of approximately 40 million doses, a filling and packaging line, a warehouse and an animal house. At the site, the Company will manufacture the enterovirus 71 (EV71) vaccine, which causes hand, foot, and mouth disease (HFMD), and its other currently marketed flu vaccines.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are pleased to complete the acquisition of this previously announced transaction, which supports our growth strategy. The Changping site will enable us to expand our production capacity, as the site will house two state- of-the-art production lines and other necessary supporting functions. We anticipate that it will take approximately two to three years for the lines to be set up and production of our commercialized flu vaccines to commence. These facilities will also support our growth objectives though the introduction of novel products by housing the production lines for our EV71 vaccine, which is currently being studied under the first clinical trial application for an HFMD vaccine submitted in China. If approved, it will be the first vaccine or antiviral treatment available for HFMD worldwide."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and Panflu.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for a number of different infectious diseases including enterovirus 71, pneumococcal disease, Japanese encephalitis, haemophilus influenzae type b (Hib), meningitis, rabies, chickenpox, mumps and rubella. Sinovac is also conducting field trials for independently developed inactivated animal rabies vaccine.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law.

    For more information, please contact:

    Sinovac Biotech Ltd.
     Helen G. Yang
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors

    The Ruth Group
     Amy Glynn/Stephanie Carrington
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media

    The Ruth Group
     Janine McCargo
     Tel:   +1-646-536-7033
     Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
2. Sinovac Provides Support to Chinas Ministry of Health to Aid Earthquake Victims
3. Sinovac Announces that Government Investigation Rules Out Healives Role in Childs Death
4. Sinovac Reports Unaudited First Quarter 2009 Financial Results
5. Sinovac Schedules 2008 Annual General Meeting
6. Sinovac Reports Unaudited Second Quarter 2009 Financial Results
7. Sinovac Wins Beijing Public Health Bureaus Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
8. Sinovacs H1N1 Vaccine Passes Experts Evaluation Organized by SFDA
9. Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea
10. Sinovac Announces Closing of Common Share Offering
11. Sinovac Announces Exercise of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... UK (PRWEB) , ... May 06, 2016 , ... ... success in changing the way the pharmaceutical industry conducts clinical trials. This month Ibs ... most influential people in pharma, and he was honored as a Tech Disruptor by ...
(Date:5/6/2016)... ... May 06, 2016 , ... US Sports Camps has ... camp held at Oregon State University this summer. Employing world-class rugby figures, including former ... all skill levels with training on key fundamentals, match play, fitness and more. , ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via Discovery Channel. ... vision of becoming a leader in optimized drug discovery through innovative cellular analysis. ...
(Date:5/6/2016)... ... May 06, 2016 , ... Online HR/benefits platforms offer a range of ... for traditional brokers and health plans. “ The Rapid Emergence of Online Benefits Firms: ... Information Services, Inc. (AIS), will offer an accurate picture of online benefits today, and ...
(Date:5/6/2016)... ... ... Canadian author Mark Black is a speaker, author, and life strategy coach who ... … with the help of his publisher Strategic Book Group and its subsidiary Publish ... bed waiting for a miracle: He needed a heart and double-lung transplant. From this came ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
Breaking Medicine Technology: